Pristinamycin in the treatment of MSSA bone and joint infection

The Journal of Antimicrobial Chemotherapy
F ValourLyon Bone and Joint Infection study group

Abstract

The aim of this study was to evaluate pristinamycin in the treatment of MSSA bone and joint infection (BJI). A retrospective, single-centre cohort study (2001-11) investigated outcome in adults receiving pristinamycin for MSSA BJI and pristinamycin-related adverse events (AEs). One hundred and two MSSA BJIs were assessed in 98 patients [chronic infection, 33.3%; and orthopaedic device-related infection (ODI), 67.6%]. Surgery was performed in 77.5% of total cases, and in all but three ODIs, associated with antibiotic therapy of a median total duration of 29.2 weeks. Pristinamycin was prescribed as a part of the initial intensive treatment phase (29.4%) and/or included in final maintenance therapy (83.3%) at a dose of 47.6 (45.5-52.6) mg/kg/day for 9.3 (1.4-20.4) weeks. AEs occurred in 13.3% of patients, consisting of gastrointestinal disorder (76.9%) or allergic reaction (23.1%), leading to treatment interruption in 11 cases. AEs were related to daily dose (OR, 2.733 for each 10 additional mg/kg/day; P = 0.049). After a follow-up of 76.4 (29.6-146.9) weeks, the failure rate was 34.3%, associated with ODI (OR, 4.421; P = 0.006), particularly when the implant was retained (OR, 4.217; P = 0.007). In most patients, the pristinamycin...Continue Reading

References

Nov 1, 1994·Journal of Clinical Epidemiology·M CharlsonJ Gold
Jan 20, 2006·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·J Kent EllingtonRobert Sherertz
Mar 11, 2009·Clinical Pharmacokinetics·Cornelia B LandersdorferFritz Sörgel
Nov 26, 2009·Médecine et maladies infectieuses·UNKNOWN la Société de Pathologie Infectieuse de Langue Française (SPILF)UNKNOWN Société Française de Rhumatologie (SFR-Rhu)
May 24, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin A Lipsky Infectious Diseases Society of America
Dec 12, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Douglas R OsmonUNKNOWN Infectious Diseases Society of America
Mar 9, 2013·BMJ Case Reports·Gaud CathoTristan Ferry
Oct 15, 2013·International Journal of Medical Microbiology : IJMM·Yvonne Mast, Wolfgang Wohlleben
Nov 20, 2013·Antimicrobial Agents and Chemotherapy·Florent ValourUNKNOWN Lyon BJI Study Group
Jun 4, 2014·The Journal of Antimicrobial Chemotherapy·Eden C CooperAmanda Gwee
Jan 22, 2015·Antimicrobial Agents and Chemotherapy·Florent ValourFrédéric Laurent
Feb 14, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F ValourUNKNOWN Lyon BJI Study Group
May 29, 2015·Clinical Microbiology Reviews·Steven Y C TongVance G Fowler

❮ Previous
Next ❯

Citations

Jul 2, 2016·The Journal of Antimicrobial Chemotherapy·Aiden J Plant, Cressida Auckland
Sep 3, 2016·The Journal of Antimicrobial Chemotherapy·F ValourUNKNOWN Lyon Bone and Joint Infection Study Group
Oct 1, 2019·Journal of Orthopaedic Trauma·Melissa DepypereUNKNOWN Fracture-Related Infection (FRI) Consensus Group
Oct 9, 2020·Expert Review of Anti-infective Therapy·Sophie Reissier, Vincent Cattoir

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.